Abbott Laboratories (NYSE:ABT) Stock Holdings Lifted by Kestra Private Wealth Services LLC

Kestra Private Wealth Services LLC grew its position in shares of Abbott Laboratories (NYSE:ABT) by 0.7% in the 4th quarter, Holdings Channel reports. The institutional investor owned 102,339 shares of the healthcare product maker’s stock after acquiring an additional 687 shares during the period. Kestra Private Wealth Services LLC’s holdings in Abbott Laboratories were worth $11,264,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Rise Advisors LLC bought a new stake in Abbott Laboratories in the fourth quarter worth approximately $37,000. Stuart Chaussee & Associates Inc. boosted its holdings in Abbott Laboratories by 236.0% in the fourth quarter. Stuart Chaussee & Associates Inc. now owns 336 shares of the healthcare product maker’s stock worth $37,000 after purchasing an additional 236 shares in the last quarter. Stonehage Fleming Financial Services Holdings Ltd acquired a new position in Abbott Laboratories during the third quarter worth $40,000. Cornerstone Planning Group LLC raised its holdings in Abbott Laboratories by 79.4% during the third quarter. Cornerstone Planning Group LLC now owns 454 shares of the healthcare product maker’s stock valued at $44,000 after buying an additional 201 shares in the last quarter. Finally, Legacy Financial Group LLC acquired a new stake in shares of Abbott Laboratories in the third quarter worth about $46,000. Institutional investors own 75.18% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ABT. Evercore ISI raised their price objective on Abbott Laboratories from $120.00 to $125.00 and gave the company an “outperform” rating in a research note on Thursday, April 4th. Barclays dropped their price target on shares of Abbott Laboratories from $141.00 to $140.00 and set an “overweight” rating on the stock in a research report on Monday, April 22nd. Royal Bank of Canada lowered their target price on shares of Abbott Laboratories from $128.00 to $125.00 and set an “outperform” rating on the stock in a research note on Thursday, April 18th. Raymond James reissued a “buy” rating and set a $124.00 target price on shares of Abbott Laboratories in a research report on Wednesday, April 24th. Finally, Citigroup raised their price target on Abbott Laboratories from $126.00 to $128.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $121.50.

Insider Activity

In other news, EVP Andrea F. Wainer sold 12,500 shares of the company’s stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $120.00, for a total value of $1,500,000.00. Following the sale, the executive vice president now directly owns 78,704 shares in the company, valued at approximately $9,444,480. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other Abbott Laboratories news, EVP Andrea F. Wainer sold 12,500 shares of Abbott Laboratories stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $120.00, for a total transaction of $1,500,000.00. Following the completion of the transaction, the executive vice president now directly owns 78,704 shares of the company’s stock, valued at $9,444,480. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP John A. Jr. Mccoy sold 472 shares of the stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $118.50, for a total transaction of $55,932.00. Following the sale, the vice president now owns 18,760 shares of the company’s stock, valued at approximately $2,223,060. The disclosure for this sale can be found here. In the last three months, insiders have sold 13,935 shares of company stock worth $1,670,048. Corporate insiders own 0.47% of the company’s stock.

Abbott Laboratories Stock Performance

Shares of NYSE ABT traded down $0.24 during mid-day trading on Monday, hitting $107.29. The company had a trading volume of 3,306,015 shares, compared to its average volume of 5,632,260. Abbott Laboratories has a 12 month low of $89.67 and a 12 month high of $121.64. The firm has a market cap of $186.17 billion, a P/E ratio of 33.42, a PEG ratio of 2.59 and a beta of 0.74. The business’s 50-day simple moving average is $113.50 and its 200-day simple moving average is $108.34. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.64 and a quick ratio of 1.16.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, April 17th. The healthcare product maker reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.96 by $0.02. The company had revenue of $9.96 billion for the quarter, compared to analyst estimates of $9.88 billion. Abbott Laboratories had a return on equity of 20.32% and a net margin of 13.96%. Abbott Laboratories’s revenue for the quarter was up 2.2% compared to the same quarter last year. During the same quarter last year, the firm earned $1.03 EPS. As a group, analysts predict that Abbott Laboratories will post 4.62 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 15th. Stockholders of record on Monday, April 15th will be issued a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.05%. The ex-dividend date of this dividend is Friday, April 12th. Abbott Laboratories’s payout ratio is 68.54%.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.